[Effectivity of intermittent RMP/EMB treatment in patients with chronic pulmonary tuberculosis (author's transl)].
59 patients with far advanced chronic pulmonary tuberculosis were treated, after a three months daily period of RMP/EMB and a third drug, with RMP 1.2 g and EMB 50 mg/kg twice weekly for the following 9 months and there after with EMB 50 mg/kg twice weekly for another 12 months. Sputumconversion was achieved in all patients within four months. Except for one bacteriological relapse during the 10th month of therapy all patients were TB-negative up to the end of at least four years (4-6 1/2 years) after onset of treatment. In nearly 78% of the patients the treatment was fully accepted and well tolerated during the first year. 8 patients had systemic reactions due to RMP between the 7th and 12th month. Only in 5 patients RMP had to be substituted by another drug. The regimen has proved to be highly effective, well acceptable and tolerable. It could be administered fully supervised.
D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008722:Methods; D008875:Middle Aged; D010507:Periodicity; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D004977:Ethambutol; D012293:Rifampin
Effektivität von intermittierender RMP- und EMB-Behandlung bei Patienten mit chronischer Lungentuberkulose (Chronikerstudie)